CARMAT

company

About

CARMAT is a medtech company that develops and manufactures bioprosthetic artificial hearts for the healthcare industry.

  • 501 - 1000

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
€30M
Industries
Health Care,Manufacturing,Medical,Medical Device
Founded date
Jan 1, 2008
Number Of Employee
501 - 1000
Operating Status
Active

CARMAT is a medtech company that develops and manufactures bioprosthetic artificial hearts for the healthcare industry. The company is offering biocompatible, auto-regulated total artificial hearts, including right and left ventricles designed to be as close as possible to the human heart. It is designed for patients suffering from chronic terminal heart failure reaching class IV on the New York Heart Association classification; or acute terminal heart failure following a massive myocardial infarction.

CARMAT’s aim is to offer a reliable new treatment and innovative therapeutic solution to heart failure patients, who are not eligible for a transplant and who have exhausted every drug-related possibility. It was launched in 2008 and is based in Vélizy-villacoublay.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
€47.50M
CARMAT has raised a total of €47.50M in funding over 2 rounds. Their latest funding was raised on Dec 19, 2022 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 19, 2022 Post-IPO Equity €15M 1 European Innovation Council Detail
Dec 19, 2022 Grant €2.50M 1 European Innovation Council Detail
Dec 18, 2018 Post-IPO Debt €30M 1 European Investment Bank Detail

Investors

Number of Lead Investors
Number of Investors
3
2
CARMAT is funded by 2 investors. European Innovation Council and European Investment Bank are the most recent investors.
Investor Name Lead Investor Funding Round
European Innovation Council Yes Post-IPO Equity
European Investment Bank Yes Post-IPO Debt